The Patent Finder

Terms ending in 2041

Ipsen Biopharm Ltd.

Every in-force patent on Ipsen Biopharm Ltd.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 12,599,549Treatment of Moderate to Very Severe Glabellar Lines and Lateral Canthal Lines
In force
 · High confidence
Galderma Holding S.A.In forceHigh confidence
US 12,642,842Therapeutic and Cosmetic Uses of Botulinum Neurotoxin Serotype E
In force
 · High confidence
Ipsen Biopharm LimitedIn forceHigh confidence
US 11,975,055Suppression of Bone Cancer-induced Allodynia
In force
 · High confidence
Ipsen Biopharm LimitedIn forceHigh confidence
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited